Licenciamento voluntário de patentes e acesso a medicamentos: o caso do sofosbuvir
DOI:
https://doi.org/10.5335/rjd.v34i1.10138Keywords:
Access to Medicines, Drug Patents, Hepatitis C, Sofosbuvir, Voluntary licensesAbstract
This paper aims to investigate empirically whether voluntary licensing of sofosbuvir can be considered an appropriate strategy for expanding access to this medicine. This research was carried out stemming from a holistic, descriptive, single-case study on the subject, according to the definitions elaborated by Robert Yin and the theoretical propositions formulated by Susan Sell. As a main result, it was possible to infer that voluntary licensing does not appear to be a strategy capable of effectively increasing access to sofosbuvir, and may even have the opposite effect by limiting competition and, thus, maximizing the licensor's patent exclusivity. Moreover, it was also possible to conclude that, in any case, this strategy cannot be considered automatically adequate for expanding access to patent protected medicines.
Downloads
Downloads
Published
Issue
Section
License
All articles are licensed under the Creative Commons Attribution-NonCommercial-NoDerivations 4.0 International license.